Bitopertin is at least 4 years away from marketing approval, if it actually manages to traverse P2 and P3. Presuming it actually makes it that far, it won't get expedited review as there is a therapy already approved (Scenesse).
Bitopertin is at least 4 years away from marketing approval, if...
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.55 |
Change
-0.170(1.15%) |
Mkt cap ! $728.6M | |||
| Open | High | Low | Value | Volume |
| $15.00 | $15.00 | $14.27 | $1.051M | 72.59K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 293 | $14.40 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.59 | 293 | 1 |
View Market Depth
| Last trade - 16.10pm 09/09/2024 (20 minute delay) ? |
| CUV (ASX) Chart |